{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE317nnn/GSE317759/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317759"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"FB23-2 exerts therapeutic effects against T-ALL through the FTO/m6A/MYC axis.","description":"T-cell acute lymphoblastic leukemia (T-ALL) is a pediatric hematological malignancy that presents significant challenges. RNA N6-methyladenosine (m6A) methylation is crucial in tumorigenesis, and the m6A demethylase FTO has emerging importance in cancers; however, its specific role in T-ALL pathogenesis remains incompletely understood. In vitro studies employed T-ALL cell lines treated with the FTO inhibitor FB23-2. Our findings indicate that FB23-2 may exert therapeutic effects against T-ALL primarily through the FTO/m6A/MYC axis.","dates":{"publication":"2026/05/19"},"accession":"GSE317759","cross_references":{"GSM":["GSM9477752","GSM9477753","GSM9477750","GSM9477751"],"GPL":["24676"],"GSE":["317759"],"taxon":["Homo sapiens"]}}